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OBJECTIVE—Ghrelin is a stomach-derived peptide that increases
food intake through the activation of hypothalamic AMP-activated
protein kinase (AMPK). However, the molecular mechanisms initi-
ated by the activation of the ghrelin receptor, which in turn lead to
AMPK activation, remain unclear. Sirtuin 1 (SIRT1) is a deacetylase
activated in response to calorie restriction that acts through the
tumor suppressor gene p53. We tested the hypothesis that the
central SIRT1/p53 pathway might be mediating the orexigenic ac-
tion of ghrelin.
RESEARCH DESIGN AND METHODS—SIRT1 inhibitors, such
as Ex527 and sirtinol, and AMPK activators, such as AICAR, were
administered alongside ghrelin in the brain of rats and mice (wild-
type versus p53 knockout [KO]). Their hypothalamic effects on
lipid metabolism and changes in transcription factors and neuro-
peptides were assessed by Western blot and in situ hybridization.
RESULTS—The central pretreatment with Ex527, a potent
SIRT1 inhibitor, blunted the ghrelin-induced food intake in rats.
Mice lacking p53, a target of SIRT1 action, failed to respond to
ghrelin in feeding behavior. Ghrelin failed to phosphorylate
hypothalamic AMPK when rats were pretreated with Ex527, as
it did in p53 KO mice. It is noteworthy that the hypothalamic
SIRT1/p53 pathway seems to be speciﬁc for mediating the
orexigenic action of ghrelin, because central administration of
AICAR, a potent AMPK activator, increased food intake in p53
KO mice. Finally, blockade of the central SIRT1 pathway did not
modify ghrelin-induced growth hormone secretion.
CONCLUSIONS—Ghrelin speciﬁcally triggers a central SIRT1/
p53 pathway that is essential for its orexigenic action, but not for
the release of growth hormone. Diabetes 60:1177–1185, 2011
G
hrelin is the only known endogenous signal
stimulating adiposity and feeding (1–3). At the
hypothalamic level, ghrelin activates AMP-
activated protein kinase (AMPK), causing rele-
vant changes in hypothalamic mitochondrial respiration
and production of reactive oxygen species (4–6), altering
the expression of transcription factors Bsx, Forkhead box
class O (FoxO1), and cAMP-responsive element–binding
protein (pCREB), and leading to the ﬁnal activation of
agouti-related peptide/neuropeptide Y (AgRP/NPY) neu-
rons. However, the molecular mechanisms occurring after
GHS-R1a activation and before AMPK phosphorylation are
completely unknown. Ghrelin is the only gut peptide with
orexigenic properties in rodents and humans; thus, the
ghrelin system is uniquely positioned as a drug target for
the treatment of cachexia. The current study tested the
hypothesis that the central sirtuin 1 (SIRT1)/p53 pathway
might be mediating the orexigenic action of ghrelin.
SIRT1 is a NAD
+-dependent deacetylase that acts on
important tumor suppressors like p53. In addition to their
biologic actions on cancer, SIRT1 and p53 are also impor-
tant in several metabolically relevant tissues. SIRT1 con-
trols divergent metabolic pathways in adipose tissue (7),
liver (8), pancreatic b cells (9), and skeletal muscle (10),
mainly through the regulation of rate-limiting enzymes in-
volved in glucose and lipid metabolism. Recent reports
have shown that central SIRT1 also regulates energy and
glucose homeostasis (11–17). On the other hand, p53 is
activated by the lack of nutrients through the activation of
AMPK, and p53 senescence activity contributes to the de-
velopment of insulin resistance (18).
Because the molecular mechanisms that link the effects
of the ghrelin/GHS-R1a system to AMPK are unknown, the
current study tested the hypothesis that the hypothalamic
SIRT1/p53 pathway might be mediating the orexigenic
action of ghrelin.
RESEARCH DESIGN AND METHODS
Animal models. MaleSprague-Dawleyrats(8weeksold,200–250g)andC57/B6
mice (8 weeks old) were housed in air-conditioned rooms (22–24°C) under
a 12/12-h light/dark cycle and fed standard chow. p53-null (8–10 weeks old,
mixed background C57BL/6J and 129/Sv) mice were described previously (19).
Homozygous wild-type (WT) and knockout (KO) mice were originated from
heterozygous mating, so only littermate WT and KO animals were compared in
each experiment. Animals were treated and killed when they were 12 to 14
weeks of age before any sign of morbidity resulting from tumor development
occurred. Animals were killed by decapitation between 1000 and 1200 h. An-
imal experiments were conducted in accordance with the standards approved
by the Faculty Animal Committee at the University of Santiago de Compostela,
and the experiments were performed in agreement with the Rules of Laboratory
Animal Care and International Law on Animal Experimentation.
Nutritional status. Rats (n = 8/group), were assigned to one of the following
groups: fed ad libitum, deprived of food for 48 h, and fasted during 48 h and
refed during 24 h. All animals had free access to tap water.
Implantation of intracerebroventricular cannulae. Rats were anesthetized
by an intraperitoneal injection of ketamine (100 mg/kg body wt)/xylazine
(15 mg/kg body wt). Mice were anesthetized by an intraperitoneal injection of
tribromoethanol (480 mg/kg; Sigma-Aldrich, St Louis, MO). Intracerebro-
ventricular cannulae were implanted stereotaxically in rats (20) or mice (21),
as described previously.
Intracerebroventricular treatments. Rats received an intracerebroventric-
ular administration of 5 mL of vehicle or ghrelin (5 mg; Bachem, Bubendorf,
Switzerland). For the inhibition of SIRT1, we used two potent speciﬁc inhib-
itors of SIRT1: Ex527 (1 to 5-10 mg in a total volume of 5 mL; Tocris
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ORIGINAL ARTICLEBioscience, St. Louis, MO) (22) and sirtinol (1 to 5-10 mg in a total volume of
5 mL; Tocris Bioscience) (23) before ghrelin administration. For the experi-
ments involving only two groups (vehicle versus ghrelin), the vehicle was
saline. For the experiments involving SIRT1 inhibitors, the vehicle was DMSO,
because Ex527 and sirtinol were both diluted in DMSO. Mice received an intra-
cerebroventricular administration of vehicle, ghrelin (5 mg), or AICAR (3 mg;
Sigma-Aldrich A9978) in a total volume of 2 mL. For the experiments involving
vehicle versus ghrelin and vehicle versus AICAR, the vehicle was saline.
We used the same dose of ghrelin for both rats and mice because this dose
has been demonstrated to be effective in both species (2). We used eight rats
per group, and the experiments were repeated at least twice. Rats were killed
by cervical dislocation. Hypothalami were dissected and stored at 280°C until
further processing.
Western blotting. Hypothalami were homogenized in ice-cold lysis buffer
containing 50 mmol/L Tris-HCl (pH 7.5), 1 mmol/L EGTA, 1 mmol/L EDTA, 1%
Triton X-100, 1 mmol/L sodium orthovanadate, 50 mmol/L sodium ﬂuoride, 5
mmol/L sodium pyrophosphate, 0.27 mol/L sucrose, 0.1% 2-mercaptoethanol,
and Complete protease inhibitor cocktail (1 tablet/50 mL; Roche Diagnostics,
Mannheim, Germany). Homogenates were centrifuged at 13,000g for 10 min at
4°C, supernatants were removed, and aliquots were snap-frozen in liquid ni-
trogen. Hypothalamus lysate (40 mg) was subjected to SDS-PAGE on 6% poly-
acrylamide gels and electrotransferred on a polyvinylidene ﬂuoride membrane.
Membranes were blocked for 1 h in TBS-Tween 20 (TBST: 50 mmol/L Tris-
HCl [pH 7.5], 0.15 mol/L NaCl, and 0.1% Tween 20) containing 5% skimmed milk
or 3% BSA (for pAMPK Thr
172 and pACC Ser
79) and probed for 16 h at 4°C in




379) with the appropriate dilution of the indicated antibodies
(acetyl-CoA carboxylase [ACC]: 1:1500; pACC: 1:2000; AMPKa1: 1:1000;
AMPKa2: 1:1000; pAMPK: 1:2000; b-actin (loading control): 1:2000). ACC was
detected using horseradish peroxidase (HRP)-conjugated–coupled streptavi-
din (Amersham Biosciences, Little Chalfont, U.K.).
Detection of proteins was performed using HRP-conjugated secondary
antibodies and an enhanced chemiluminescence reagent (Amersham Bio-
sciences). We used 8 to 12 hypothalami per experimental group. Acetyl-p53-
Lys
379 was obtained from Cell Signaling (Danvers, MA). ACCa, pACCa-Ser
79,
AMPKa1, and AMPKa2 were obtained from Upstate Biotechnology (Teme-
cula, CA); pAMPKa-Thr
172 from Cell Signaling; fatty acid synthase (FAS),
pCREB, and FoxO1 from Santa Cruz Biotechnology (Santa Cruz, CA); and
b-actin from Abcam (Cambridge, U.K.), as described previously (6).
Fortheblotting assays,theexperimentsconstituted bytwogroups:Sprague-
Dawley rats and mice (WT and p53 KO) treated with ghrelin or AICAR and
analyzed using a nonparametric Mann–Whitney test. In the experiments con-
stituted by four groups (Sprague-Dawley rats treated with vehicle, ghrelin,
Ex527, and Ex527 + ghrelin, or with vehicle, ghrelin, sirtinol, and sirtinol +
ghrelin), the data were analyzed by two-way ANOVA, followed by a post hoc
multiple comparison test (Tukey’s test).
In situ hybridization. Coronal hypothalamic sections (16 mm) were cut on
a cryostat and immediately stored at 280ºC until hybridization. For AgRP,
NPY, and Bsx mRNA detection, we used the speciﬁc antisense oligodeox-
ynucleotides (Table 1). These probes were 39-end–labeled with [
35S]deoxy-
ATP using terminal deoxynucleotidyl transferase. The speciﬁcity of the probes
was conﬁrmed by incubating the sections with an excess of the unlabeled
probes, as reported previously (24,25). In situ hybridizations were performed
as reported previously (24,25).
The frozen sections were ﬁxed with 4% paraformaldehyde in phosphate
buffer (0.1 mol/L, pH 7.4) at room temperature for 30 min. They were dehy-
drated using 70%, 80%, 90%, 95%, and 100% ethanol for 5 min each. The hy-
bridization was done overnight at 37°C in a moist chamber. The hybridization
solution contained 5 3 10
5 (AgRP and Bsx) or 1 3 10
6 cpm (NPY) per slide of
the labeled probe, 43 standard saline citrate (SSC), 50% deionized formamide,
13 Denhardt’s solution, 10% dextran sulfate, and 10 mg/mL sheared, single-
stranded salmon sperm DNA.
Afterward, the hybridization sections were sequentially washed in 13 SSC
at room temperature, four times in 13 SSC at 42ºC (30 min/wash), and once in
13 SSC at room temperature (1 h) and then rinsed in water and ethanol. Fi-
nally, the sections were air-dried and exposed to Hyperﬁlm b-Max (Amersham
Biosciences) at room temperature for 4 to 6 days for AgRP and NPY and for 21
days for Bsx. The slides were developed in Kodak D-19 developer (Eastman
Kodak Co., Rochester, NY), ﬁxed (Kodak ﬁxer), and counterstained with
methylene blue.
To compare anatomically similar regions, the slides were matched ac-
cording to Paxinos and Watson (26). The slides from control and treated
animals at each treatment time were always exposed to the same autoradio-
graphic ﬁlm. All sections were scanned, and the speciﬁc hybridization signal
was quantiﬁed by densitometry using the Molecular Analyst digital imaging
system (Bio-Rad Laboratories Inc., Richmond, CA). The optical density of the
hybridization signal was determined and subsequently corrected by the optical
density of its adjacent background value. For this reason, a rectangle with the
same dimensions in each case was drawn enclosing the hybridization signal
over each nucleus and over adjacent brain areas of each section (back-
ground). We used 16 to 20 sections for each animal (4–5 slides, 4 sections/
slide). The mean of these 16 to 20 values was used as the densitometry value
for each animal.
Plasma growth hormone response. Chronic intracerebroventricular and
intracardiac cannulae were implanted under ketamine/xylazine anesthesia, as
described above. After surgery, the animals were placed directly in isolation
test chambers for 5 days and were given free access to regular rat chow and tap
water. Ontheday oftheexperiment, bloodsamples(0.3mL)werewithdrawn at
the appropriate times. The animals (n =7 –9 rats/group) received vehicle,
ghrelin (12 nmol/kg i.v.), Ex527 (1 mg i.c.v.), or Ex527 + ghrelin.
Hormone assays. Plasma growth hormone (GH) concentrations were de-
termined by double-antibody radioimmunoassay using materials supplied by
the National Hormone Pituitary Program, as described previously (27). Values
are expressed in terms of the GH reference preparation (GH-RP-2). The intra-
and interassay coefﬁcients of variation were 7 and 10%, respectively.
Statistical analysis and data presentation. The experiments constituted by
two groups: Sprague-Dawley rats and mice (WT and p53 KO) treated with
ghrelin or AICAR and analyzed using a nonparametric Mann–Whitney test. In
the experiments constituted by four groups (Sprague-Dawley rats treated with
vehicle, ghrelin, Ex527, and Ex527 + ghrelin, and vehicle, ghrelin, sirtinol, and
sirtinol + ghrelin), the data were analyzed by two-way ANOVA, followed by
a post hoc multiple comparison test (Tukey’s test). Data are expressed as
mean 6 SEM and analyzed using PASW Statistics 18.0 software (SPSS Inc.,
Chicago, IL). A value of P , 0.05 was considered as being signiﬁcant.
RESULTS
Regulation of SIRT1 by nutritional status. Rats fasted
during 48 h exhibited a loss of body weight, whereas the
refeeding during 24 h partially led to a substantial recovery
(Fig. 1A). Acetyl-p53 levels, a marker of SIRT1 activity in
vivo (28), were decreased in the hypothalamus of fasted
rats (F2,18 = 3.651, P , 0.05), whereas those levels were
similar to baseline in rats after refeeding (Fig. 1B). Be-
cause ghrelin is a key player for increasing feeding be-
havior, we tested the hypothesis that central ghrelin
administration might stimulate hypothalamic SIRT1 activ-
ity. As previously reported, ghrelin increased food intake
after 2 h (F1,13 = 24.161, P , 0.001; Fig. 1C)a n d6h( F1,13 =
36.14, P , 0.001; Fig. 1E) (29) and decreased hypothalamic
acetyl-p53 levels after 2 h (F1,13 = 7.915, P , 0.01; Fig. 1D)
and 6 h (F1,13 = 7.645, P , 0.05; Fig. 1F).
Blockade of the SIRT1/p53 pathway blunts the orexi-
genic action of ghrelin. We next studied the functional
relevance of these ﬁndings by assessing whether the
pharmacologic blockade of SIRT1 activity might regulate
the orexigenic action of ghrelin. First, we observed that
the central injection of Ex527, a potent inhibitor of SIRT1
TABLE 1
Antisense oligonucleotides for in situ hybridization analysis





1178 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgFIG. 1. Effects of nutritional status on hypothalamic SIRT1. A: Fasting for 48 h caused a signiﬁcant (P < 0.001) decrease in body weight, whereas
refeeding during 24 h partially recovered the weight loss. B: Hypothalamic acetylated p53 levels decreased in fasted rats and recovered in refed
rats. Effects of intracerebroventricular ghrelin injection (5 mg/rat) after 2 h on food intake (C), and hypothalamic acetylated p53 levels (D).
Effects of intracerebroventricular ghrelin injection (5 mg/rat) after 6 h on food intake (E), and hypothalamic acetylated p53 levels (F). Values
were normalized to those of the internal control b-actin, and the results are expressed as arbitrary units. Mean values were obtained from six
animals per group. Values are the mean 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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ferent doses (1, 5, and 10 mg; Supplementary Fig. 1A), in-
dicating that this compound decreased hypothalamic SIRT1
activity in vivo. We then centrally administered ghrelin,
Ex527, and Ex527 + ghrelin to the rats. We found that
ghrelin increased food intake at 2 h (data not shown) and
6h( F3,27 = 12.282, P , 0.001; Fig. 2A), but when the SIRT1
inhibitor was administered 20 min before ghrelin, the
orexigenic action of ghrelin was markedly blunted after 6 h
(Fig. 2A). Because ghrelin increases food intake through
its effects on hypothalamic fatty acid metabolism (5,6), we
next assessed the levels of several key enzymes for the
synthesis of lipids. We found that 6 h after an intrace-
rebroventricular ghrelin injection, pAMPK levels were in-
creased (F3,28 = 2.455, P , 0.05), but ACC levels were
decreased (F3,27 = 6.045, P , 0.01). Those effects were
abolished when the SIRT1 inhibitor was coadministered
(Fig. 2B and C).
It is important to note that even though pAMPK levels
were increased, pACC did not reach statistical signiﬁ-
cance, probably because of the different kinetics of phos-
phorylation of both enzymes (6). Furthermore, the higher
expression of the transcription factors FoxO1 (F3,27 =
2.509, P , 0.05), pCREB (F3,26 = 3.668, P , 0.05; Fig. 2D),
and Bsx (F3,26 = 3.526, P , 0.05; Fig. 2E and F) and the
neuropeptides NPY (F(3,26) = 4.362, P , 0.05) and AgRP
(F3,26 = 3.33, P , 0.05; Fig. 2E and F) in the hypothalamic
arcuate nucleus induced by ghrelin was also abolished
when the SIRT1 inhibitor was coadministered. When we
used sirtinol, another inhibitor of SIRT1 activity, results
were similar to those obtained with Ex527 (Supplementary
Fig. 1).
Tumor suppressor protein p53 is a substrate of SIRT1,
and it is found hyperacetylated in SIRT1 KO mice (30).
Because a recent report showed that p53 is involved in
energy metabolism and homeostasis (31), we next inquired
FIG. 2. Pharmacologic blockade of SIRT1 blunts the orexigenic action of ghrelin. A: Effects of intracerebroventricular ghrelin injection (5 mg/rat),
Ex527 (1 mg/rat), and ghrelin + Ex527 on food intake after 6 h. Hypothalamic protein levels of pAMPKa, AMPKa1, AMPKa2, pACC, ACCa, FAS
(B and C), pCREB, FoxO1 (D), and Bsx, NPY, and AgRP (E and F) after 6 h of ghrelin and Ex527 injection. Values were normalized to those of the
internal control b-actin, and the results are expressed as arbitrary units. Mean values were obtained from six animals per group. Values are the
mean 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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effects of ghrelin. For this purpose, we treated WT and
p53 KO mice with intracerebroventricular ghrelin, fol-
lowing the same protocol as that described above. The
p53 KO mice did not show alterations in body weight,
food intake, fat mass, or nonfat mass compared with WT
littermates (Supplementary Fig. 2A–D). As expected,
central ghrelin administration increased food intake in
WT animals, whereas identical intracerebroventricular
ghrelin treatment in p53 KO animals had no effect on food
intake after 2 (Fig. 3A)o r6h( F i g .3 B).
We next assessed the levels of several key enzymes for
the synthesis of lipids. No principal differences were found
between WT and p53 KO mice regarding the expression of
AMPKa1, AMPKa2, or FAS (Fig. 3C and D). It is note-
worthy that we found that 6 h after its central injection,
ghrelin increased pAMPK levels in WT mice (F1,12 =4 . 4 6 6 ,
P , 0.05) but failed to do so in p53 KO mice (Fig. 3C and D),
suggesting that p53 is an essential mediator of ghrelin
actions on AMPK. The levels of pAMPK and pACC are
correlated in normal conditions; however, we found that the
hypothalamic levels of pACC are downregulated in p53 KO
mice (F1,12 =8 . 5 7 6 ,P , 0.01) but not in WT mice (Fig. 3C
and D).
Although we do not have a clear explanation for these
results, it seems that ghrelin is able to activate ACC when
FIG. 3. Mice lacking p53 do not respond to ghrelin injection. Effects of intracerebroventricular ghrelin injection (5 mg/mouse) on food intake after
2h( A) and 6 h (B) in WT and p53 KO mice. Hypothalamic protein levels of pAMPKa, AMPKa1, AMPKa2, pACC, ACCa, and FAS after 6 h of ghrelin
injection (C and D). Values were normalized with to those of the internal control b-actin, and the results are expressed as arbitrary units. Mean
values were obtained from six animals per group. Values are the mean 6 SEM. *P < 0.05, **P < 0.01.
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the actions of ghrelin on different key enzymes modulating
fatty acid metabolism. Further studies analyzing not only
protein levels but also enzymatic activity and lipolysis/
lipogenesis will be necessary to address this issue. Fur-
thermore, we detected that central ghrelin injection de-
creased ACCa levels in both WT (F1,12 = 2.844, P , 0.05)
and p53 KO mice (F1,12 = 6.699, P , 0.01; Fig. 3C and D),
indicating that p53 is not essential for ghrelin-mediated
ACC regulation.
p53 does not mediate the orexigenic action of AICAR.
Central injection of AICAR, a potent activator of AMPK
activity, stimulates food intake in rodents (32). To de-
termine whether p53 is a crucial player for the orexigenic
action of AICAR, we centrally treated p53 KO mice with
AICAR (3 mg) and found a stimulation in food intake after
6h( F1,12 = 3.542, P , 0.05; Fig. 4A). Hypothalamic pAMPK
levels were also increased in p53 KO mice treated with
AICAR (F1,12 = 4.479; Fig. 4B and C). Therefore, our data
indicate that p53 is not required for the orexigenic action
of direct AMPK activators.
The central SIRT1 pathway does not modulate ghrelin-
induced GH secretion. Finally, we assessed whether the
SIRT1 pathway is mediating other neuroendocrine actions
of ghrelin, namely GH secretion. Administration of ghrelin
(27) led to the expected increase in plasma GH levels at
5, 10, and 15 min (Fig. 5A), whereas the central blockade of
SIRT1 did not alter that response (Fig. 5A). Ghrelin ex-
hibited a similar stimulatory effect in both area under the
curve and mean peak GH levels (Fig. 5B and C).
DISCUSSION
Our current data demonstrate that the hypothalamic SIRT1/
p53 pathway is crucial for the orexigenic effect of ghrelin.
Pharmacologic inhibition of SIRT1 or genetic depletion of
p53 abolish the effects of ghrelin on AMPK and thereby
blunt ghrelin-induced effects on transcription factors, in-
cluding pCREB, FoxO1, and Bsx, and neuropeptides, such
as NPY and AgRP, leading to a suppression of ghrelin-
induced food intake.
SIRT1 is a deacetylase that regulates metabolism in
multiple peripheral tissues. It has been reported recently
that SIRT1 mRNA is located in metabolically relevant areas
of the mouse neuroaxis, such as pro-opiomelanocortin neu-
rons, which are critical for energy and glucose homeostasis
(11). It seems that SIRT1 regulates the central melano-
cortin system (13) and that the speciﬁcl a c ko fS I R T 1i n
the brain abolishes the higher physical activity induced by
calorie restriction (12). More speciﬁcally, the lack of SIRT1
FIG. 4. Central injection of AICAR increases food intake in p53 KO mice. A: Effects of intracerebroventricular AICAR injection (3 mg/mouse) on
food intake after 6 h in p53 KO mice. B and C: Hypothalamic protein levels of pAMPK, pACC, AMPKa1, AMPKa2, ACCa, and FAS after 6 h of
AICAR injection. Values were normalized to those of the internal control b-actin, and the results are expressed as arbitrary units. Mean values
were obtained from six animals per group. Values are the mean 6 SEM, *P < 0.05.
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to diet-induced obesity because of reduced energy ex-
penditure (17). Concurring with those data, we observed
that acetylation of p53 in the hypothalamus is decreased
after food deprivation, indicating that SIRT1 as a deacety-
lase increased its hypothalamic activity during starvation.
Therefore, the regulation of hypothalamic SIRT1 activity
by nutritional status is similar to its regulation in several
peripheral tissues (33).
Ghrelin is a stomach-derived hormone that rapidly
increases food intake and body weight (1,29). Its regula-
tion by nutritional status was controversial because the
assays detected both acyl-ghrelin and des-acyl ghrelin and
thus were not speciﬁc. Studies using new technologies for
separately detecting both isoforms indicate that circulating
des-acyl ghrelin increases signiﬁcantly with fasting,
whereas blood acyl-ghrelin levels are not changed over the
course of fasting (34,35). Most of the effects of ghrelin are
exerted through the GH secretagogue receptor 1a (GHS-
R1a) (36), which is expressed in AgRP/NPY neurons in the
hypothalamic arcuate nucleus (37). The orexigenic effect
of ghrelin is mediated by AMPK, a key upstream master
regulator of lipid metabolism (5,6). However, the molecu-
lar events regulating AMPK phosphorylation after the ac-
tivation of the GHS-R1a are unknown.
In the present work, we demonstrate that central ghrelin
administration increases hypothalamic SIRT1 activity, stim-
ulating the deacetylation of p53. More interestingly and
consistent with previous ﬁndings (14), the blockade of
central SIRT1 activity abolished the potent orexigenic ef-
fect of ghrelin. At molecular level, the ghrelin-induced
activation of AMPK is prevented when SIRT1 activity is
blocked. The interaction between SIRT1 and AMPK has
been previously shown in vitro, indicating that resveratrol
activates AMPK in neurons (38).
Although pharmacologic experiments based on the ad-
ministration of SIRT1 inhibitors to animal models are
providing important insight into principal effects, targets,
and mechanisms of the SIRT1 system, understanding the
function of its endogenous role requires more sophisti-
cated approaches, such as genetic disruption of SIRT1 or
its substrates. We focused on p53 because this tumor-
suppressor protein is a well-known target of SIRT1 action,
and there is growing evidence of its role on metabolism
and energy balance in peripheral tissues (31). Our results
indicate that p53 is required for the ghrelin-induced food
intake, because ghrelin failed to increase food intake in
p53 KO mice. In accordance with pharmacologic ﬁndings,
ghrelin stimulated hypothalamic pAMPK levels in WT mice
but failed to do so in p53 KO mice. On the other hand, it has
been shown that SIRT1 is a target gene of p53 in some but
not all of the tissues (31,39), so it might be possible that p53
mediates the changes in SIRT1 upon ghrelin treatment or
calorie restriction. However, the observed correlation be-
tween acetylated p53 and SIRT1 activity in the hypothala-
mus on different experimental conditions indicate that
p53 is an essential mediator of SIRT1-dependent effects of
ghrelin on AMPK. Mice lacking p53 in speciﬁc hypothalamic
areas will be essential to demonstrating which particular
neuronal circuits are responsible for those actions. How-
ever, the central SIRT1/p53 pathway is not required by di-
rect AMPK activators, because AICAR stimulated food
intake in p53-deﬁcient mice. Therefore, these ﬁndings cor-
roborate that the central SIRT1/p53 pathway is not associ-
ated with AICAR-induced activation of AMPK.
Finally, our results indicate that ghrelin stimulated GH
release as expected, but the blockade of central SIRT1 did
not modify GH levels. Therefore, it seems that the central
SIRT1/p53 pathway is speciﬁcally mediating the ghrelin
orexigenic action and suggests that different neuronal
pathways modulate ghrelin-induced food intake and GH
secretion.
FIG. 5. Pharmacologic blockade of SIRT1 does not modify the ghrelin-
induced GH secretion. A: Effects of intravenous ghrelin injection (12
nmol/kg), intracerebroventricular Ex527 (1 mg/rat), and ghrelin +
Ex527 on plasma GH levels in adult male freely moving rats. Area under
the curve (AUC) (B) and mean peak GH (C) levels. Mean values were
obtained from six animals per group. Values are the mean 6 SEM. *P <
0.05, **P < 0.01.
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logic and genetic evidence to demonstrate that the central
nervous system SIRT1/p53 pathway is essential for the
orexigenic response to ghrelin (Fig. 6). The molecular path-
way mediating those effects involves alterations in AMPK
activation, which leads to changes in hypothalamic fatty
acid metabolism, and ﬁnally, modiﬁes feeding behavior.
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